Accueil   Diary - News   All news ERYTECH ANNOUNCES LAUNCH OF INVESTIGATOR-INITIATED PHASE 2 STUDY OF ERYASPASE (GRASPA®)

ERYTECH ANNOUNCES LAUNCH OF INVESTIGATOR-INITIATED PHASE 2 STUDY OF ERYASPASE (GRASPA®)

ERYTECH Pharma a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the launch of an investigator-initiated study to evaluate eryaspase, also known by the trade name GRASPA®, in patients with acute lymphoblastic leukemia (ALL). The study will take place in seven Nordic countries and be conducted in collaboration with the Nordic Society of Pediatric Hematology and Oncology (NOPHO).

 

Read the press release